Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site

No abstract is available for this paper.

• Publication year

  2018

• Venue

  bioRxiv

• Publication date

  2018-01-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/prot.25496PMID 29569753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Structure of the Human CFTR Ion Channel.

  2017cited by this paper
• Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.

  2017cited by this paper
• From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations

  2016cited by this paper
• The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.

  2016cited by this paper
• Insights into Disease-Associated Mutations in the Human Proteome through Protein Structural Analysis.

  2015cited by this paper
• The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation

  2015cited by this paper
• Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening

  2015cited by this paper
• "Cystic fibrotics could survive cholera, choleraics could survive cystic fibrosis"; hypothesis that explores new horizons in treatment of cystic fibrosis.

  2015cited by this paper
• Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity

  2015cited by this paper
• Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics

  2015cited by this paper
• VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.

  2014cited by this paper
• Correctors of F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein

  2014cited by this paper
• Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention

  2014cited by this paper
• Cystic fibrosis genetics: from molecular understanding to clinical application

  2014cited by this paper
• Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene

  2013cited by this paper
• A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

  2013cited by this paper
• Mechanism-based corrector combination restores ΔF508-CFTR folding and function

  2013cited by this paper
• VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

  2013cited by this paper
• Corrector VX-809 stabilizes the first transmembrane domain of CFTR.

  2013cited by this paper
• Identification and validation of hits from high throughput screens for CFTR modulators.

  2012cited by this paper
• Barrier Mechanisms in the Developing Brain

  2012cited by this paper
• Functional Rescue of F508del-CFTR Using Small Molecule Correctors

  2012cited by this paper
• Hypothesis: Cystic fibrosis carrier geography reflects interactions of tuberculosis and hypertension with vitamin D deficiency, altitude and temperature. Vitamin D deficiency effects and CF carrier advantage.

  2012cited by this paper
• Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.

  2012cited by this paper
• Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

  2012cited by this paper
• ABCMdb: A database for the comparative analysis of protein mutations in ABC transporters, and a potential framework for a general application

  2012cited by this paper
• The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

  2011cited by this paper
• Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

  2011cited by this paper
• Cystic Fibrosis

  2009cited by this paper
• Clustering of disease-causing mutations on the domain-domain interfaces of ABCC6.

  2009cited by this paper
• Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

  2009cited by this paper
• Molecular models of the open and closed states of the whole human CFTR protein

  2009cited by this paper
• CFTR function and prospects for therapy.

  2008cited by this paper
• Evaluating candidate agents of selective pressure for cystic fibrosis

  2007cited by this paper
• Domain interdependence in the biosynthetic assembly of CFTR.

  2007cited by this paper
• In vivo phosphorylation of CFTR promotes formation of a nucleotide‐binding domain heterodimer

  2006cited by this paper
• Cystic fibrosis.

  2005cited by this paper
• CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains

  2005cited by this paper
• Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand.

  2005cited by this paper
• Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs.

  2002cited by this paper
• Cation-π interactions in structural biology

  1999cited by this paper
• Cation-pi interactions in structural biology.

  1999cited by this paper
• CYSTIC FIBROSIS HETEROZYGOTE RESISTANCE TO CHOLERA TOXIN IN THE CYSTIC FIBROSIS MOUSE MODEL

  1995cited by this paper
• Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model.

  1994cited by this paper
• Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

  1989cited by this paper
• Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA

  1989cited by this paper
• Amino‐aromatic interactions in proteins

  1986cited by this paper

• Correction of a Traffic-Defective Missense ABCB11 Variant Responsible for Progressive Familial Intrahepatic Cholestasis Type 2

  2025cites this paper
• Unifying perspectives on the activity and genotypic targeting of pharmacological chaperones

  2025cites this paper
• The lipid bilayer strengthens the cooperative network of membrane proteins

  2025cites this paper
• Lung cancer biomarkers.

  2025cites this paper
• Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review

  2025cites this paper
• Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators

  2025cites this paper
• Caries Experience of People with Cystic Fibrosis: A Systematic Review.

  2024cites this paper
• Effects of stand-alone polar residue on membrane protein stability and structure.

  2024cites this paper
• Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

  2024cites this paper
• Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants

  2024cites this paper
• Elexacaftor/VX-445–mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics

  2023cites this paper
• Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

  2023cites this paper
• The Effect of Complex Alleles of the CFTR Gene on the Clinical Manifestations of Cystic Fibrosis and the Effectiveness of Targeted Therapy

  2023cites this paper
• Potency of Anti-fibrotic Herbs on Fibrogenesis: A theoretical evaluation

  2023cites this paper
• Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants

  2023influential citation
• Advancements in artificial intelligence and machine learning in revolutionising biomarker discovery

  2023cites this paper
• Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs

  2023cites this paper
• Exploring the Mechanism of Activation of CFTR by Curcuminoids: An Ensemble Docking Study

  2023cites this paper
• Lipid Bilayer Strengthens the Cooperative Network of a Membrane-Integral Enzyme

  2023cites this paper
• Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model

  2022cites this paper
• Pharmacological Responses of the G542X-CFTR to CFTR Modulators

  2022influential citation
• Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation.

  2022cites this paper
• High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients

  2022cites this paper
• Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment

  2021cites this paper
• Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants

  2021cites this paper
• The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue

  2021cites this paper
• Discovery of CFTR modulators for the treatment of cystic fibrosis

  2021cites this paper
• Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTATM

  2021cites this paper
• Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands

  2021cites this paper
• CFTR corrector efficacy is associated with occupancy of distinct binding sites

  2021cites this paper
• Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator

  2021cites this paper
• A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

  2021cites this paper
• Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants

  2021cites this paper
• Antisense Oligonucleotide Therapy to Correct CFTR Function in People with Cystic Fibrosis

  2021cites this paper
• Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR

  2021cites this paper
• Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity.

  2020cites this paper
• Co-translational folding of the first transmembrane domain of ABC-transporter CFTR is supported by assembly with the first cytosolic domain

  2020cites this paper
• Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator

  2020cites this paper
• Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators

  2020cites this paper
• Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings

  2020cites this paper
• Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination

  2020cites this paper
• Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing

  2020cites this paper
• The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor

  2020cites this paper
• The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis

  2020cites this paper
• Functional and Pharmacological Characterization of the Rare CFTR Mutation W361R

  2020cites this paper
• Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis

  2019cites this paper
• The influence of CFTR complex alleles on precision therapy of cystic fibrosis.

  2019cites this paper
• Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.

  2019cites this paper
• Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation

  2019cites this paper
• ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel

  2019cites this paper
• Mechanics and pharmacology of substrate selection and transport by eukaryotic ABC exporters

  2019cites this paper
• R560S: A class II CFTR mutation that is not rescued by current modulators.

  2019cites this paper